This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
HCPLive
MAY 20, 2024
A numerically slower decline in eGFR was reported in the finerenone cohort after hospitalization for heart failure when compared with placebo.
116 
Medical Xpress - Cardiology
DECEMBER 19, 2023
Heart failure is causally associated with chronic kidney disease (CKD), according to a study published online Dec. 11 in PLOS ONE.
Cardiovascular Diabetology
MARCH 21, 2025
Mineralocorticoid receptor antagonists (MRAs) are often underutilized in patients with heart failure (HF), particularly those with diabetes and/or chronic kidney disease (CKD). However, the impact of concurren.
Open Heart
OCTOBER 31, 2024
Background Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Results Baseline characteristics revealed significant differences between NUA and HUA groups, with the latter exhibiting a higher prevalence of males, chronic kidney disease (CKD) and elevated levels of various biomarkers.
Medical Xpress - Cardiology
MARCH 7, 2025
Patients with chronic kidney disease (CKD) and heart failure have higher rates of inpatient dialysis initiation than those without heart failure, according to a study published online Feb. 18 in Mayo Clinic Proceedings.
HCPLive
MARCH 26, 2025
Other risk factors in the population included PZA or ETB use, hypertension, heart failure, and chronic kidney disease.
112 
American College of Cardiology
MARCH 31, 2025
25 in Chicago and simultaneously published in JACC.
Circulation
SEPTEMBER 10, 2024
Early identification of kidney dysfunction in patients with advanced heart failure is crucial for timely interventions. In addition to elevations in serum creatinine, kidney dysfunction encompasses inadequate maintenance of sodium and volume homeostasis, retention of uremic solutes, and disrupted endocrine functions.
Science Daily - Heart Disease
FEBRUARY 14, 2025
New research shows sotagliflozin is the only drug in its class to demonstrate these results.
114 Circulation
JANUARY 27, 2025
METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.
Cardiovascular Diabetology
JUNE 14, 2024
Diabetic kidney disease is an established risk factor for heart failure. However, the impact of incident heart failure on the subsequent risk of renal failure has not been systematically assessed in diabetic p.
HCPLive
SEPTEMBER 26, 2024
Rates of absolute and functional iron deficiency were high among adults in the US, even in those without anemia, heart failure, or chronic kidney disease.
105 
Science Daily - Heart Disease
DECEMBER 16, 2024
atrial fibrillation (AF), a heart condition that causes an irregular heartbeat in the upper chambers of the heart, affects up to one in three people in their lifetime. Significant complications associated with this condition include ischemic stroke, heart failure, myocardial infarction, chronic kidney disease, dementia and mortality.
Cardiovascular Diabetology
JANUARY 8, 2024
Myocardial infarction (MI), stroke, peripheral arterial disease (PAD), heart failure (HF) and chronic kidney disease (CKD) are common cardiovascular renal diseases (CVRD) manifestations for type 2 diabetes.
European Journal of Heart Failure
NOVEMBER 26, 2024
Discontinuation and reinitiation of mineralocorticoid receptor antagonists (MRA) in patients with heart failure and reduced ejection fraction (HFrEF). BMI, body mass index; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association.
HCPLive
NOVEMBER 11, 2024
Panelists discuss the criteria for identifying at-risk patients for chronic kidney disease (CKD) testing in type 2 diabetes and review the screening and detection tests, emphasizing the critical importance of early detection through blood and urine tests for both CKD management and heart failure prevention.
European Journal of Heart Failure
FEBRUARY 5, 2025
Meta-analysis on the main outcomes of angiotensin receptorneprilysin inhibitor (ARNI) in heart failure (HF) patients with end-stage kidney disease (ESKD) on dialysis. Abstract Aims Angiotensin receptorneprilysin inhibitor (ARNI) has played an increasingly important role in the management of heart failure (HF).
Frontiers in Cardiovascular Medicine
DECEMBER 18, 2023
Chronic kidney disease coexists in up to 40%–50% of patients with chronic heart failure cases. There are guidelines for patients with heart failure and chronic kidney disease separately, but they do not specifically address patients with concomitant heart failure and kidney disease.
93 Journal of the American Heart Association
FEBRUARY 24, 2025
Journal of the American Heart Association, Ahead of Print.
Circulation
NOVEMBER 11, 2024
Introduction:Smoking is a well-known risk factor for atherosclerotic cardiovascular disease and kidney failure among patients with chronic kidney disease (CKD). However, the association of former and current smoking status (vs.
American College of Cardiology
FEBRUARY 5, 2024
Hypertension represents a major modifiable risk factor for coronary artery disease (CAD), heart failure (HF), stroke, chronic kidney disease (CKD), and dementia.
75 
Cardiovascular Diabetology
AUGUST 6, 2024
Data on major cardiovascular events (MACE; mortality, myocardial infarction, stroke, heart failure) through December 2021 were obtained from national registries. Furthermore, compared with other GLD, the use of cardioprotective GLD was more common in patients with a less frequent history of heart failure (5.0%
Journal of the American Heart Association
DECEMBER 24, 2024
Journal of the American Heart Association, Ahead of Print. The index date was the first CKD stage 3b/4 diagnosis with 1 hyperkalemia diagnosis and 1 serum potassium >5.0 mmol/L in the preceding 12 months (baseline) for patients with hyperkalemia and a randomly selected CKD stage 3b/4 diagnosis for controls.
Circulation: Heart Failure
NOVEMBER 25, 2024
Circulation: Heart Failure, Volume 17, Issue 12 , Page e011629, December 1, 2024. Spironolactone, a steroidal mineralocorticoid receptor antagonist (MRA), has been used to treat patients with heart failure (HF) for more than half a century. The use of MRAs has been limited due to excessive concern about hyperkalemia.
Open Heart
APRIL 24, 2024
Introduction Heart failure (HF) incidence is increasing in older adults with high hospitalisation and mortality rates. Frailty, chronic kidney disease and ischaemic heart disease increased significantly versus the first period (p<0.001). Treatment is complicated by side effects and comorbidities.
Open Heart
JUNE 1, 2022
Objectives We aim to assess the association of cardiovascular medications with outcomes of patients referred to the diagnostic heart failure (HF) clinic with symptoms or signs of possible HF, raised N-terminal pro-brain-type natriuretic peptide (NT-proBNP) but no evidence of HF on transthoracic echocardiography (TTE).
Circulation
MARCH 9, 2025
Albuminuriaincreased urine albumin excretionis associated with cardiovascular mortality among patients with diabetes, hypertension, chronic kidney disease, or heart failure, as well as among adults with few cardiovascular risk factors. Circulation, Volume 151, Issue 10 , Page 716-732, March 11, 2025.
MIBHS
FEBRUARY 15, 2025
Secondary hypertension : This type results from an underlying condition such as kidney disease, hormonal disorders, or the use of certain medications. The Link Between High Blood Pressure and Heart Health Your heart and blood vessels form a complex network that ensures oxygen and nutrients reach every part of your body.
Journal of the American Heart Association
JANUARY 12, 2024
ABSTRACT: Albuminuria, an established biomarker of the progression of chronic kidney disease, is also recognized as a biomarker for the risk of cardiovascular disease. Elevated urinary albumin excretion indicates kidney damage and systemic vascular disease, including myocardial capillary disease and arterial stiffness.
Open Heart
JULY 20, 2022
Aims Heart failure (HF) is associated with comorbidities which independently influence treatment response and outcomes. post-MDT; p<0.001), initiation of renin–angiotensin aldosterone system inhibitors in HF with reduced ejection fraction (HFrEF) with advanced chronic kidney disease (9% pre vs 71% post-MDT; p<0.001).
Circulation
NOVEMBER 11, 2024
A 35-year-old gravida 1, para 0 with biventricular heart failure (LVEF 25%), nonischemic cardiomyopathy, history stroke, history of left ventricular thrombus, class III obesity, and chronic kidney disease who had been followed by Cardio-Obstetrics throughout her pregnancy presented at 34 weeks gestation for planned induction of labor.
Circulation: Heart Failure
MARCH 8, 2024
Circulation: Heart Failure, Ahead of Print. Background:Current prevalence estimates of heart failure (HF) are primarily based on self-report or HF hospitalizations. Overt cardiovascular disease, which ranged from 2.1% (HF) to 13.6% (atrial fibrillation), was less common. were female, 25.6% were Black, 12.8%
The American Journal of Cardiology
OCTOBER 5, 2024
Publication date: Available online 5 October 2024 Source: The American Journal of Cardiology Author(s): Meghana Iyer, Khaled Ziada, Leslie Cho, Jacqueline Tamis-Holland, Umesh Khot, Amar Krishnaswamy, Rishi Puri, Samir Kapadia, Grant W Reed
American College of Cardiology
FEBRUARY 12, 2024
What is the value of the new American Heart Association’s (AHA’s) PREVENT equation(s) for primary prevention that use routinely available clinical variables including obesity, diabetes, kidney disease, and social risk for predicting 10- and 30-year absolute risk of cardiovascular disease (CVD) including each atherosclerotic CVD (ASCVD) and heart (..)
Circulation
NOVEMBER 11, 2024
Introduction:The treatment of heart failure (HF) with hydralazine-isosorbide dinitrate (H-ISDN) in African Americans (AA) with New York Heart Association (NYHA) III-IV who remain symptomatic despite optimal medical therapy is a class Ia indication.
Cardiometabolic Health Congress
NOVEMBER 16, 2023
Key findings presented at the conference included disparities in access to kidney transplantation and waitlisting based on race and neighborhood characteristics, racial and ethnic differences in incident chronic kidney disease (CKD), and the use of motivational strategies to improve dialysis nonadherence among African American patients.
Heart BMJ
OCTOBER 10, 2024
The association between AF and various conditions—including hypertension, heart failure, sleep apnoea and chronic kidney disease—is well-described, highlighting that AF is often a multisystem disorder. 2 Before the.
Circulation: Cardiovascular Quality & Outcomes
DECEMBER 6, 2023
Background:Overall outcomes and the escalation rate for home hospital admissions for heart failure (HF) are not known. had chronic kidney disease, and 60.6% Circulation: Cardiovascular Quality and Outcomes, Ahead of Print. were women, and 64.8% were White. Of the cohort, 29.2% had reduced ejection fraction, 50.9%
The British Journal of Cardiology
JULY 17, 2024
2–4 The studies will be well-known to nephrologists and demonstrated that angiotensin-receptor blockers (ARBs) had anti-proteinuric effects and/or slowed the decline of kidney function in patients with diabetic kidney disease. Clinicians and health care systems must be encouraged to make use of these treatments.”
Circulation
JANUARY 24, 2024
METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.
European Journal of Heart Failure
MARCH 4, 2024
Patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) have a high risk of developing LRTI. Empagliflozin reduced the risk of lower respiratory tract infections. CI, confidence interval; HR, hazard ratio. Aims Lower respiratory tract infections (LRTI) are common worldwide.
Circulation
NOVEMBER 11, 2024
However, multi-parametric techniques and biomarkers which are available for investigating cardiovascular diseases and kidney diseases may offer opportunities for the evaluation of CRS. Circulation, Volume 150, Issue Suppl_1 , Page A4147019-A4147019, November 12, 2024.
Circulation
NOVEMBER 11, 2024
Patients with hyperkalemia had a higher frequency of diabetes mellitus, hypertension, chronic liver disease, acute kidney injury, chronic kidney disease, end-stage renal disease, and acute encephalopathy (p<0.001).
40 
The British Journal of Cardiology
OCTOBER 8, 2024
Several recent clinical trials have provided evidence that these agents can decrease the risk of, and slow progression of, cardiovascular and renal diseases independently of their glucose-lowering and weight-lowering effects.
40
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content